Amgen stock gains as FDA approval and price targets land

Published on 09/19/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock closed at USD 385.65 on September 18, 2026, with a 1.55 percent gain. BMO cut the rating to Market Perform on September 8, 2026, while the FDA approved reduced monitoring for Imdelltra on September 14, 2026.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) closed at USD 385.65 on September 18, 2026, up 1.55 percent, with a market capitalization of USD 208.49 billion. The key move this week came from two separate updates: MarketScreener showed the stock near its 52-week high of USD 447.03, while MarketBeat reported that BMO Capital Markets cut Amgen to Market Perform from Outperform on September 8, 2026, with a USD 450 price target.

FDA approval adds a fresh catalyst

Amgen's most concrete operational update in the past week came on September 14, 2026, when MarketScreener flagged FDA approval for reduced monitoring time for the first two doses of Imdelltra. The same company page also listed Amgen's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, which keeps the stock tied to both regulation and investor messaging.

For investors, the detail that matters is not only the approval itself but the balance between product progress and analyst caution. MarketBeat showed a consensus target price of USD 381.32 and a consensus rating of Hold, while the stock finished above that level at USD 385.65 on September 18, 2026.

Revenue, EPS and guidance

Amgen last reported quarterly earnings on August 4, 2026, and MarketBeat said the company earned USD 6.29 per share, above the USD 5.62 consensus by USD 0.67. Revenue reached USD 10.05 billion, up 9.5 percent from the prior year, and Amgen set FY 2026 EPS guidance at USD 22.30 to USD 23.50.

That mix leaves a simple read-through: the stock trades close to its yearly high, the latest quarter beat estimates, and the rating backdrop is still mixed. MarketBeat also put Amgen's one-year low at USD 269.77 and the one-year high at USD 447.03, with 8,426,111 shares traded in the latest session it showed.

Price stays close to highs

Amgen stock closed at USD 385.65 on September 18, 2026, after opening at the same level on Nasdaq, and the move left it 17.82 percent higher for 2026. With market cap at USD 208.49 billion and the 52-week range still stretching from USD 269.77 to USD 447.03, the chart remains elevated even after the September pullback.